CHOOSE FONT SIZE:

FOLLOW US ON:

 

John Sylvester

Curriculum Vitae

For a printer friendly version, click here: Dr. John Sylvester, CV

CURRICULUM VITAE

JOHN EDWARD SYLVESTER, M.D.

Prostate Cancer Treatment Center
1-877-330-7722
Email: js@drjohnsylvester.com

CURRENT STATUS
Medical Director
(July 2009-present) 		Prostate Cancer Treatment Center
Clinical Research Director
(2008-2009) 		Seattle Prostate Institute
Director
(2006-2008) 		Seattle Prostate Institute
Director - Education/Training
(1997-2006) 		Seattle Prostate Institute
Radiation Oncologist
(1988-2009) 		Swedish Cancer Institute, Seattle, WA
Director
(1991-2002) 		Puget Sound Tumor Institute
Chief Medical Officer
(2000-present) 		Pro-Qura
Employee/Member
(1989-2009) 		Tumor Institute Radiation Oncology Group

EDUCATION
  Undergraduate: 1975-80 UCSB, Santa Barbara, CA, (B.A. Biological Sciences)
  Medical School: 1980-84 UCLA, Los Angeles, CA
  Internship: 1984-85 USC, Huntington Memorial Hospital, (Internal Medicine)
  Residency: 1985-88 UCLA Department of Radiation Oncology, 1987-88 Chief Resident

HONORS AND AWARDS
1987-88 American Cancer Society Fellowship

PROFESSIONAL SOCIETIES
1991 American College of Radiation Oncology
1988 Southwest Oncology Group
1988 National Cancer Institute
1988 Washington State Medical Association
1988 King County Medical Society
1988 American College of Radiology
1987 American Society of Therapeutic Radiology & Oncology
1985 American Medical Association
2004 American Brachytherapy Society

LICENSES / CERTIFICATIONS
License: State of Washington Physician and Surgeons License: 25438 June 1988, California 2009, Florida 2009, Alaska 2009
Board Status: Board Certified – American College of Radiology, May 1988.
  American Board of Radiology - Radiation Oncology, 1988.

RESEARCH PROTOCOLS
Dosimetric and morbidity outcomes of Cs-131 brachytherapy in combination with external beam radiation therapy in subjects with intermediate to high risk adencocarcinoma of the prostate: An observational study. Principal Investigator. current
Pd-103 dose de-escalation for early stage prostate cancer: A prospective randomized trial. Principal Seattle Investigator. current
Dosimetric and morbidity outcomes of Pd-103 brachytherapy in combination with external beam radiation therapy in subjects with intermediate to high risk adencocarcinoma of the prostate: An observational study. Principal Investigator. current
Implant and external radiation for prostate cancer with or without hormonal therapy: A prospective randomized trial. Principal Investigator. closed
Cystoscopy techniques in prostate brachytherapy: Effects on urinary function. Sub-Investigator. completed
Permanent prostate brachytherapy using Cs-131 for localized prostatic carcinoma: A phase II study. Principal Investigator. closed
Interstitial adenovirus therapy for locally recurrent adenocarcinoma of the prostate following external beam radiation therapy. Principal Seattle Investigator. closed
Concurrent hyperfractionated radiation therapy with weekly chemotherapy for advanced carcinoma of the head and neck. Principal Investigator. closed

SELECTED PRESENTATIONS
American Society for Therapeutic Radiation and Oncology, 42nd Annual Meeting, Boston, MA, October 2000.
125-Iodine/103-Palladium Brachytherapy With or Without Neoadjuvant Androgen Ablation for Early Stage Prostate Cancer. ASTRO Conference Boston, MA. 10/00.
The Role of Androgen Ablation in Patients With Biochemical Failure Following External Beam Radiation. 1st Annual International Conference on Androgen Deprivation Therapy in Management of Prostate Cancer Sarasota FL. 11/00.
The Role of Androgen Ablation Combined With Radiation Therapy or Surgery in Early Stage Prostate Cancer. Grand Rounds. Stevens Hospital. Edmonds, WA. 2/22/01.
The Role of Radiation Therapy in Prostate Cancer. Benefits Healthcare Cancer Care 2001. Great Falls, MT 4/5/01.
Results & Comparisons: Management of Biochemical Failures. 4th Annual Advanced Prostate Brachytherapy Conference. Seattle, WA. 4/20/01.
Role of Androgen Ablation in Permanent Seed Implantation for the Treatment of Early Stage Prostate Cancer, 4th Annual Advanced Prostate Brachytherapy Conference. Seattle, WA. 4/21/01.
Ten-Year Biochemical Relapse-Free Survival Following Brachytherapy + External Beam Radiotherapy for Patients with Localized Prostate Cancer: The Seattle Experience, Dutch Urologic Association, Amsterdam, The Netherlands, October 2001.
Brachytherapy in the Treatment of Prostate Cancer, 4th Annual Stockton Cancer Care Symposium, Stockton, CA, 2/23/02.
Recent Advances in Radiation Therapy in the Treatment of Prostate Cancer, International Center for Post-Graduate Medical Education, Atlanta, GA, 6/7/02.
Recent Advances in Radiation Therapy in the Treatment of Prostate Cancer, International Center for Post-Graduate Medical Education, Houston, TX, 6/14/02.
Overview of Permanent Seed Implantation in the Treatment of Prostate Cancer, American Society for Therapeutic Radiation and Oncology, 43rd Annual Meeting, San Francisco, October 2001.
How to Avoid Jamming Rapid™ Strands, 5th Annual Advanced Prostate Brachytherapy Conference. Seattle, WA. 4/12/02.
Technique of Prostate Seed Implantation, 6th Annual Advanced Prostate Brachytherapy Conference. Seattle, WA. 4/12/02.
Recent Advances in the Management of Prostate Cancer: The Year in Review, International Center for Post-Graduate Medical Education, San Diego, CA, 10/19/02.
Ten-Year BRFS in Patients Treated with EBRT + I125/PD103 Seed Implantation for Early Stage Prostate Cancer, American Society for Therapeutic Radiation and Oncology, 44th Annual Meeting, New Orleans, October 2002.
DeWeese T, Arterbery E, Michalski J, Sylvester, JE, Terris M, Wilding G, Yu DC, Moore L, Kimball L, Ando D, and Kirn D: “A Phase I/II Dose Finding Trial of the Intraprostatic Injection of CG7870, a Prostate-Specific Antigen Cytolyic Adenovirus in Patients With Locally Recurrent Prostate Cancer Following Definitive Radiotherapy and/or Seed Brachytherapy”, 11th International Conference Therapy of Cancer of Cancer. San Diego, CA. 12/12/02-12/14/02.
Monotherapy vs. Combined Implantation + EBRT for Early Stage Prostate Cancer, 8th Annual Scottsdale Prostate Cancer Symposium, Scottsdale, AZ, 2/28/03.
Technical Innovation in the Seattle Preplan Technique, 8th Annual Scottsdale Prostate Cancer Symposium, Scottsdale, AZ, 2/28/03.
Permanent Prostate Brachytherapy, Australian Brachytherapy Society, Melbourne, Australia, 4/5/03.
Temporary Prostate Brachytherapy, Australian Brachytherapy Society, Melbourne, Australia, 4/5/03.
Permanent Prostate Brachytherapy, British Association of Urologic Surgeons Annual Meeting, Manchester, England, 6/26/03.
Monotherapy vs. Combined Implantation + EBRT for Early Stage Prostate Cancer, 3rd Annual International Prostate Cancer Congress, Bermuda, 7/19/2003.
Prostate Cancer Monotherapy with Permanent Seed Implantation, 8th Annual International Prostate Cancer Conference, Harvard University, July 2003.
15 year Biochemical Relapse-Free Survival Following External Beam Radiation Therapy and Brachytherapy Boost. American Brachytherapy Society Annual Meeting, Barcelona, May 2004.
15 year Biochemical Relapse-Free survival following External Beam Radiation Therapy and Brachytherapy Boost. American Society of Clinical Oncology; New Orleans, June 2004.
Urologic Society of Australasia, Annual Meeting, Melbourne. Keynote Speaker, Feb 2005.
Brachytherapy: The Gold Standard for Prostate Cancer Treatment in the Twenty-first Century (Debate). World Congress of Endourology, Amsterdam August 2005.
Combination EBRT plus Brachytherapy in Prostate cancer. 12th Annual Prostate Cancer Meeting Scottsdale AZ, February 2007
Prostate Brachytherapy Techniques. American Brachytherapy Society 28th Annual Meeting, Chicago, IL, April/May 2007.
Influence of Pro-Qura-Generated Plans on Postimplant Dosimetric Quality: A Review of a Multi-Institutional Database. 2008 World Congress of Brachytherapy Annual Meeting, Boston, MA, May, 2008.
Secondary Malignancies following radiation therapy for prostate cancer. 14th Annual Prostate Cancer Meeting Scottsdale AZ, March 2009
IMRT approaches to Prostate Cancer. 14th Annual Prostate Cancer Meeting Scottsdale AZ, March 2009
Prostate Brachytherapy outcomes. Keynote speaker. Annual Urologic Symposium Freiburg, Germany, May 2009
Randomized Trial Comparing Intra-operative Flexible, Rigid and no Cystoscopy After Prostate Brachytherapy. American Brachytherapy Society 28th Annual Meeting, Toronto, CA, May/June 2009.
Prostate brachytherapy biochemical relapse free survival outcomes in intermediate risk prostate cancer patients. American Brachytherapy Society 28th Annual Meeting, Toronto, CA, May/June 2009.
One to 3 lectures, every year, at Seattle Prostate Institute’s Annual Advanced Prostate Brachytherapy Conference from 1997 through 2009

BIBLIOGRAPHY
Sylvester JE, “Irradiation Can Stop the Growth of Heterotopic Bone”, Radiology Today 4(3): 1 & 3, March 1987.
Sylvester JE, Greenberg P, Selch M, Thomas B, Amstutz HC: “The Use of Postoperative Irradiation for the Prevention of Heterotopic Bone Formation After Total Hip Replacement”, Int J Rad Onc Biol Phys, 14(3): 471-476, 1988.
Ragde H, Blasko J.C., Schumacher D, Grimm P.D., Cunningham D.L., Sylvester J, Mate T.P., “Use of Transrectal Ultrasound in Transperineal Iodine 125 Seeding for Prostate Cancer: Methodology.” J. Endourol. 3:209; 1989.
Sylvester JE: “Technical Considerations in the Use of Prophylactic Radiation Therapy to Prevent Heterotopic Bone Formation”, Seminars in Arthroplasty, 3(3): 167-171, July 1992.
Grimm, PD; Blasko, JC; Ragde, HR; Sylvester, JE; Mate, T: “Migration of Iodine-125 and Palladium-103 Seeds to the Lung After Transperineal Brachytherapy for Prostate Cancer.” Endocurie/Hyperthermia, Oncol. 9:50;1993.
Blasko J, Ragde H, Cavanagh W, Sylvester J, Grimm P: “Long-term Outcomes of External Beam Irradiation and 1-125/Pd-103 Brachytherapy Boost for Prostate Cancer” Int J Rad Onc Biol Phys, vol 36, number 1,suppl. 1996.
Grimm P, Blasko J, Ragde H, Sylvester J, Clarke D: “Does Brachytherapy Have a Role in Treatment of Prostate Cancer?”, Hematology/Oncology Clinics of North America, Vol.10(3):653-673, June 1996.
Blasko J, Ragde H, Luse R, Sylvester J, Cavanagh W, Grimm P: “Should Brachytherapy be Considered a Therapeutic Option in Localized Prostate Cancer?” The Urologic Clinics of North America, Vol. 23(4): 633-650, November 1996.
Ragde H, Blasko J, Grimm P, Kenny G, Sylvester b, Hoak D, Landin K, Cavanagh W: “Interstitial Iodine-125 Radiation Without Adjuvant Therapy for Clinically Localized Prostate Cancer”, Cancer. 80(3):442-53, 1997 Aug. 1.
Blasko JC, Ragde H, Grimm PD, Sylvester JE, Cavanagh W: “Potential for Neoadjuvant Hormonal Therapy with Brachytherapy for Prostate Cancer”, Molecular Urology. Vol.1 Numbers 2/3,1997.
Sylvester JE, Blasko J, Grimm P, Ragde H: “Interstitial Implantation Techniques in Prostate Cancer”, Journal of Surgical Oncology 1997; 66:65-75.
Mettlin, CJ, Murphy, GP, Sylvester, J, McKee, RF, Morrow M, Winchester DP, Results of hospital registry surveys by the American College of Surgeons: outcomes of prostate cancer treatment by radical prostatectomy”, Cancer, Nov.1997, 80:1875-81.
Ragde H, Blasko JC, Grimm PD, Kenny GM, Sylvester J, et al.: “Brachytherapy for clinically localized prostate cancer: results at 7- and 8- years follow-up”, Seminars in Surgical Oncology. 13(60): 438-43, Nov-Dec 1997.
Grimm P, Blasko J, Ragde H, Sylvester J, Cavanagh W: “Transperineal Ultrasound Guided 125 I, 103 Pd Brachytherapy in the Management of Localized Prostate Cancer: Update of the Clinical Experience at Eight Years”, for submission to Int J Rad Onc Biol Phys, March 1998.
Sylvester JE, Grimm PD, Blasko JC, et al.: “Urethral Visualization During Transrectal Ultrasound Guided Interstitial Implantation for Early Stage Prostate Cancer.” Submitted to Radiology 1998, abstract RSNA Dec 1998 presentation.
Tapen E, Blasko J, Grimm P, Haakon R, Luse R, Clifford S, Sylvester J, Griffin T. “Reduction of Radioactive Seed Embolization to the Lung Following Prostate Brachytherapy”. International Journal of Radiation Oncology, Biology and Physics, Vol 42 No.5 pp. 1063-1067 1998.
Sylvester JE, Blasko JC, Grimm PD, et al: “Neoadjuvant Androgen Ablation combined with External Beam Radiation Therapy and Brachytherapy in early stage Prostate Cancer” Molecular Urology. Vol. 3 No. 3 pp. 231-238 1999.
Sylvester JE, Grimm PD, Blasko JC : Brachytherapy as Monotherapy, Textbook “Prostate Cancer” Lippincott Williams and Wilkins. For publication in the fall of 1999.
Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W. “Palladium-103 Brachytherapy for Prostate Cancer” Int. J Radiation Oncology Biol. Phys., Vol. 46, No 4, pp. 839-850, 2000.
Sylvester JE, Blasko JC, Grimm PD, Meier R, Cavanagh W. “Short Course Androgen Ablation Combined with External Beam Radiation Therapy and Low Dose Rate Permanent Brachytherapy in Early Stage Prostate Cancer: A Matched Subset Analysis”, Molecular Urology, 2000 Fall;4(3):155-9; Discussion 161.
Cavanagh W, Blasko JC, Grimm PD, Sylvester JE. “Transient Elevation of Serum Prostate- Specific Antigen Following 125I/103Pd Brachytherapy for Localized Prostate Cancer” Seminars in Urologic Oncology, Vol. 18, No 2, pp. 160-165, May 2000.
Blasko JC, Grimm PD, Sylvester JE, Cavanagh W. “The Role of External Beam Radiotherapy With I-125/Pd-103 Brachytherapy for Prostate Carcinoma” Radiotherapy & Oncology, Vol. 57, pp. 273-278, December 2000.
Sylvester JE, Grimm PD, Blasko JC, Meier R, Grier D, Heaney C, Cavanagh W. “Urethral Visualization During Transperineal Interstitial Brachytherapy for Early Stage Prostate Cancer” Journal of Brachytherapy International, Vol. 16, pp. 145-150, April-June 2000.
Sylvester JE, Grimm PD, Blasko JC, Meier R, Spiegel J, Heaney C, Cavanagh W. “The Role of Androgen Ablation in Patients With Biochemical or Local Failure After Definitive Radiation Therapy: A Survey of Practice Patterns of Urologists and Radiation Oncologists in the United States”, Molecular Urology, Vol. 58, No. 2A, pp. 71-77, August 2001.
Carroll PR, Fair WR, Grossfeld GD, Heston WD, Lieberman R, Malkowicz SB, Stricker HJ, Sylvester J, Peehl DM, Meyer F, Hard C, “Overview consensus statement”, Urol., 58:1-4.
Grimm PG, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. “10-Year Biochemical (Prostate-Specific Antigen) Control of Prostate Cancer With 125I Brachytherapy”, International Journal of Radiation Oncology Biology, Vol. 51, No. 1, pp. 31-40, 2001.
Grimm PD, Blasko JE, Sylvester JE. “Clinical Selection Issues for Permanent Seed Prostate Brachytherapy” J. of Brachytherapy International, Vol. 16, No. 3, pp. 143-152, July-September 2001.
Sylvester JE, Blasko JE, Grimm b, Meier R, Heaney C, Cavanagh W. “Impact of Short-Course Androgen Ablation on the Biochemical Progression-Free Survival of High-Risk Prostate Cancer Patients Managed With Permanent Brachytherapy” J. of Brachytherapy International, Vol. 16, No. 2, pp. 173-180, July September 2001.
Sylvester JE, Blasko JC, Grimm PD, Meier R. “Transperineal Permanent Brachytherapy for Local Recurrence Following External Beam Radiation for Early Stage Prostate Cancer,” J. of Brachytherapy International, Vol. 16, No. 2, pp. 181-188, July-September 2001.
Sylvester JE, Blasko JC, Grimm PD. “Brachytherapy as Monotherapy, In Prostate Cancer Principles & Practice,” Koss, Isaacs & Scher (eds.), Lippincott, Williams & Wilkins, Philadelphia, PA, pp. 336-357, 2002.
Blasko JC, Mate T, Sylvester JE, Grimm PD, Cavanagh W. “Brachytherapy for Carcinoma of the Prostate: Techniques, Patient Selection, and Clinical Outcomes,” Seminars in Radiation Oncology, Vol. 12, No 1, pp. 81-94, January 2002.
Sylvester JE, Blasko JC, Grimm PD, et al. “Ten-Year Biochemical Relapse-Free Survival Following External Beam Radiation and Brachytherapy for Localized Prostate Cancer: The Seattle Experience,” International Journal of Radiation Oncology Biology Physics, 2003; 57:4:944-952.
Han BH, Wallner K, Merrick G, Butler W, Sutlief S, Sylvester J. "Prostate Brachytherapy Seed Identification On Post-Implant TRUS Images,” Medical Physics, 2003 May; 30(5):898-900.
Sylvester J., Blasko J., Grimm P., “Transrectal Ultrasound-Guided Prostate Brachytherapy,” in Image-Guided Diagnosis and Treatment of Cancer (D’Amico A, Loeffler J., Harris J. eds), Totowa, Humana Press, 2003, pp. 119-154.
Grimm PG, Blasko JC, Sylvester JE, The Prostate Cancer Treatment Book. New York. McGraw Hill. 2004.
Sylvester JE. “Prostate Brachytherapy,” North American Pharmaco Therapy, Business Briefing; pp. 51-53, Feb 2004.
Grimm PD, Blasko JC, Sylvester JE, et al. “Technical Improvement in Permanent Seed Implantation: A Two Stage Brachytherapy System. Description and Comparison With Current Technique,” Brachytherapy, Vol. 3, No1, pp. 34-40, May 2004.
Sylvester JE, Blasko JC, Grimm PD, et al; “Fifteen Year Follow-up of the First Cohort of Localized Prostate Cancer Patients Treated With Brachytherapy,” Journal of Clinical Oncology; 22:14S:4567, 2004.
Grimm PD, Sylvester JE, “Advances in Brachytherapy,” Reviews in Urology; Vol. 6, Supp 4, pp. S37-S48, 2004.
Sylvester JE, Valicenti RK; Review of article “Hormonal Therapy Plus External-Beam Radiation and Brachytherapy for Prostate Cancer,” Oncology Vol. 19, No 1, pp.36-39.
Sylvester JE, Grimm PD, Malmgren JA: “Fifteen Year Biochemical Relapse Free Survival Outcomes of Patients With Localized Prostate Cancer Treated With Brachytherapy”, British Journal of Urology International abstract, February 2005.
Sylvester JE; The Seattle Prostate Institute Approach to Treatment Planning for Permanent Implants; In Dicker AP et al (ed), Basic and Advanced Techniques in Prostate Brachytherapy, Martin Dunitz Taylor & Francis Group, Independence, KY, 2005.
Sylvester JE, Blasko JC, Grimm PD, et al; “Fifteen Year Outcomes of Prostate Cancer Patients Treated With Brachytherapy,” BJU abstract 2005.
Grimm PG, Merrick GS, Butler WM, Blasko JC, Sylvester JE, Allen ZA, Chaudhry U, Mazza A. “Preliminary Analysis of the Pro-Qura Multi-Institutional Prostate Brachytherapy Dosimetry Database,” Brachytherapy abstract Vol. 5, No 2, pp. 91, April-June 2006.
Liauw SL, Sylvester JE, Morris CG, Blasko JC, Grimm PD, “Second Malignancies After Prostate Brachytherapy: Incidence of Bladder and Colorectal Cancers in Patients with Fifteen Years of Potential Follow-up,” International Journal of Radiation Oncology Biology Physics 2006;66:3:669-673.
Sylvester JE, Grimm PG, Blasko JC, Millar J, Orio III PF, Skoglund S, Galbreath RW, Merrick G, “15-Year Biochemical Relapse Free Survival in Clinical Stage T1-T3 Prostate Cancer Following Combined External Beam Radiotherapy and Brachytherapy; Seattle Experience,” International Journal of Radiation Oncology Biology Physics 2007;67:1:57-64.
Merrick GS, Grimm PD, Sylvester J, Blasko JC, et al. “Initial analysis of Pro-Qura: A multi-institutional database of prostate brachytherapy dosimetry,” Brachytherapy 2007; 6(1):9-15.
Steven J. Frank, Peter D. Grimm, John E. Sylvester, Gregory S. Merrick, Brian J. Davis, Anthony Zeitman, Brian J. Moran, David C. Beyer, Mack Roach III, Daniel H. Clarke, Richard G. Stock, W. Robert Lee, Jeff M. Michalski, Kent E. Wallner, Mark Hurwitz, Louis Potters, Deborah A. Kuban, Bradley R. Prestidge, Robyn Vera, Shannon Hathaway, John C. Blasko. “Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States,” Brachytherapy 2007; 6(1):2-8.
John Sylvester, Tricia Zeller, Chris J. Hennessy, Steve Eulau, Peter Grimm. Overview of the Calypso® 4D Localization System™ American College of Radiation Oncology Practice Management Guide, American College of Radiation Oncology, Bethesda, MD 2008.
John Sylvester, Gregory S. Merrick, Peter Grimm, et al: “Influence of Pro-Qura Feedback on Rectal Dosimetry Following Permanent Prostate Brachytherapy,” 2008 World Congress of Brachytherapy, May 3-6, 2008. Brachytherapy, Vol. 7, No. 2, pp. 121, April-June 2008.
Allen Z, Merrick GS, Grimm P, Blasko J, Sylvester J, Butler W, Chaudry UU, Sitter M. “Influence of Pro-Qura-Generated Plans on Postimplant Dosimetric Quality: A Review of a Multi-Institutional Database,” Medical Dosimetry, 2008 Autumn; 33(3):206-14.
John Sylvester, Gregory S. Merrick, Peter Grimm, et al: “Influence of Pro-Qura Feedback on Rectal Dosimetry Following Permanent Prostate Brachytherapy,” 2008 World Congress of Brachytherapy, May 3-6, 2008. Brachytherapy abstract, Vol. 7, No. 2, pp. 121, April-June 2008.
Jesse N. Aronowitz, Juanita M. Crook, Jeff M. Michalski, John E. Sylvester, Gregory S. Merrick, Christie Mawson, David Pratt, Devi Naidoo, Wayne M. Butler, Kathryn Karolczuk. “Inter-institutional variation of implant activity for permanent prostate brachytherapy,” Brachytherapy 2008;7:297-300.
C. Louiselle, G.S. Merrick, J. Sylvester, P. Grimm, S. Eulau, M. Waheed, Z.A. Allen, W.M. Butler. “Analysis of the Pro-Qura Database: Implant Quality, Brachytherapist Experience and Rectal Dose Parameters,” ASTRO 50th Annual Meeting abstract, Boston, MA, September 21-25, 2008. International Journal of Radiation Oncology Biology Physics; 72: (1): S326.
John Sylvester, Peter D. Grimm, Stephen M. Eulua, Robert K. Takamiya, Devi Naidoo. “Permanent Prostate Brachytherapy Preplanned technique: The modern Seattle Method Step by Step and Dosimetric Outcomes,” 2008 World Congress of Brachytherapy, May 3-6, 2008. Brachytherapy, Vol. 7, No. 2, April-June 2008.
Tward JD, Sylvester JE, Grimm PD, Schrieve DC “The Risk of Second Primary malignancies Following Brachytherapy Monotherapy, External Beam Plus Brachytherapy, or Radical Prostatectomy for Prostate Cancer” International Journal of Radiation Oncology Biology Physics;2008, 72: (1):S208
Orio PF 3rd, Merrick GS, Grimm P, Blasko J, Sylvester J, Allen ZA, Butler WM, Chaudhry UU. “Effects of the time interval between prostate brachytherapy and postimplant dosimetric evaluation in community practice: analysis of Pro-Qura database,” Am J Clin Oncology 2008 Dec 31(6):523-31.
Loiselle CR, Waheed M, Sylvester J, et al. “Analysis of the Pro-Qura Database: rectal dose, implant quality and brachytherapist’s experience,” Brachytherapy 2009 Jan-Mar; 8(1):34-9.
Sylvester JE, Grimm PD, Eulau SM, et al. “Permanent prostate brachytherapy preplanned technique: The modern Seattle method step-by-step and dosimetric outcomes,” Brachytherapy 2009 Apr-Jun;8(2):197-206.
Gregory S. Merrick, Zachariah A. Allen, John E. Sylvester. “Post-implant rectal dosimetry is not dependent on Pd103 or I125 seed activity,” Brachytherapy abstract, Vol. 8, No. 2, pp. 125, May 30-June 2, 2009.
John E. Sylvester, Jason Wong, Erik Torgerson, et al. “Randomized trial comparing intra-operative flexible, rigid and no cystoscopy after prostate brachytherapy,” Brachytherapy abstract, Vol. 8, No. 2, pp. 168, May 30-June 2, 2009.
John E. Sylvester, Peter D. Grimm, Jason Wong, et al. “Prostate brachytherapy biochemical relapse free survival outcomes in intermediate risk prostate cancer patients,” Brachytherapy abstract, Vol. 8, No. 2, pp. 140, May 30-June 2, 2009.
John E. Sylvester M.D., Peter D. Grimm D.O., Jason Wong M.D., et al. “15 year Biochemical Relapse-Free Survival following I125 Prostate Brachytherapy in Clinically Localized Prostate Cancer: Seattle Experience,” accepted for publication and presentation at the 51st American Society for Radiation Oncology Annual Meeting, abstract, Chicago, IL, November 1-5, 2009.
Jason Wong M.D., John E. Sylvester M.D., Peter D. Grimm D.O., et al. “First report on the use of a thinner I125 radioactive seed that fits into 20 gauge needles for permanent seed prostate brachytherapy: A report on post-implant dosimetry and acute toxicity,” accepted for publication and presentation at the Canadian Association of Radiation Oncologists Annual Meeting, abstract, Toronto, CA, November, 2009.
Jason Wong M.D., John E. Sylvester M.D., Peter D. Grimm D.O., et al. “First report on the use of a thinner I125 radioactive seed that fits into 20 gauge needles for permanent seed prostate brachytherapy: A report on post-implant dosimetry and acute toxicity,” accepted for publication and presentation at the 51st American Society for Radiation Oncology Annual Meeting, abstract, Chicago, IL, November 1-5, 2009.